PURPOSE: To examine the ability and mechanism of the 16 kDa N-terminal fragment of human prolactin (16K hPRL) in the inhibition of abnormal retinal neovascularization. METHODS: The 16K hPRL-encoding sequence was inserted into an adenoviral vector (16K-Ad). Western blot analysis verified the expression of 16K hPRL and inhibition of proliferation, confirming functional activity of the 16K hPRL in virus-infected adult bovine aortic endothelial (ABAE) cells. 16K hPRL inhibited retinal neovascularization in a mouse model of oxygen-induced retinopathy. The ability of recombinant 16K hPRL expressed in E. coli (r16K hPRL) was compared to that of endostatin in inducing apoptosis of cultured human retinal endothelial cells (HREC). RESULTS: 16K was expressed in virus-infected ABAE cells and resulted in a dose-dependent inhibition of cell proliferation. Eyes injected with 16K-Ad showed a reduction in preretinal neovascularization of 82.3 +/- 9.3% (P < 0.00001) when compared to uninjected controls. r16K hPRL was 100 times more potent than endostatin in inducing apoptosis in HRECs. CONCLUSIONS: Intravitreal administration of 16K hPRL inhibited neovascularization in the mouse model of oxygen-induced retinopathy. 16K hPRL stimulated apoptosis in HRECs and inhibited cell proliferation in ABAE cells. These results suggested a potential therapeutic role for 16K hPRL in the treatment of proliferative retinopathies.
PURPOSE: To examine the ability and mechanism of the 16 kDa N-terminal fragment of human prolactin (16K hPRL) in the inhibition of abnormal retinal neovascularization. METHODS: The 16K hPRL-encoding sequence was inserted into an adenoviral vector (16K-Ad). Western blot analysis verified the expression of 16K hPRL and inhibition of proliferation, confirming functional activity of the 16K hPRL in virus-infected adult bovine aortic endothelial (ABAE) cells. 16K hPRL inhibited retinal neovascularization in a mouse model of oxygen-induced retinopathy. The ability of recombinant 16K hPRL expressed in E. coli (r16K hPRL) was compared to that of endostatin in inducing apoptosis of cultured human retinal endothelial cells (HREC). RESULTS: 16K was expressed in virus-infectedABAE cells and resulted in a dose-dependent inhibition of cell proliferation. Eyes injected with 16K-Ad showed a reduction in preretinal neovascularization of 82.3 +/- 9.3% (P < 0.00001) when compared to uninjected controls. r16K hPRL was 100 times more potent than endostatin in inducing apoptosis in HRECs. CONCLUSIONS: Intravitreal administration of 16K hPRL inhibited neovascularization in the mouse model of oxygen-induced retinopathy. 16K hPRL stimulated apoptosis in HRECs and inhibited cell proliferation in ABAE cells. These results suggested a potential therapeutic role for 16K hPRL in the treatment of proliferative retinopathies.
Authors: Ngoc-Quynh-Nhu Nguyen; Sebastien P Tabruyn; Laurence Lins; Michelle Lion; Anne M Cornet; Florence Lair; Francoise Rentier-Delrue; Robert Brasseur; Joseph A Martial; Ingrid Struman Journal: Proc Natl Acad Sci U S A Date: 2006-09-14 Impact factor: 11.205
Authors: Luz Consuelo Zepeda-Romero; Miguel Vazquez-Membrillo; Elva Adan-Castro; Francisco Gomez-Aguayo; Jose Alfonso Gutierrez-Padilla; Eusebio Angulo-Castellanos; Juan Carlos Barrera de Leon; Cesareo Gonzalez-Bernal; Manuel Alejandro Quezada-Chalita; Alonso Meza-Anguiano; Nundehui Diaz-Lezama; Gonzalo Martinez de la Escalera; Jakob Triebel; Carmen Clapp Journal: Pediatr Res Date: 2016-11-14 Impact factor: 3.756
Authors: Edith Arnold; José C Rivera; Stéphanie Thebault; Daniel Moreno-Páramo; Hugo Quiroz-Mercado; Andrés Quintanar-Stéphano; Nadine Binart; Gonzalo Martínez de la Escalera; Carmen Clapp Journal: Diabetes Date: 2010-09-07 Impact factor: 9.461
Authors: Nundehui Díaz-Lezama; Zhijian Wu; Elva Adán-Castro; Edith Arnold; Miguel Vázquez-Membrillo; David Arredondo-Zamarripa; Maria G Ledesma-Colunga; Bibiana Moreno-Carranza; Gonzalo Martinez de la Escalera; Peter Colosi; Carmen Clapp Journal: Lab Invest Date: 2015-11-16 Impact factor: 5.662